Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life

Last updated: May 7, 2025
Sponsor: Yale University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urinary Incontinence

Bladder Disorders

Genitourinary Prolapse

Treatment

Bladder instillation with Irrisept

Clinical Study ID

NCT06163469
2000034836
000
No NIH funding
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main questions are:

  1. is instillation of 150mL of CGH for five-minute duration at the time of SPC exchange feasible in an outpatient setting and tolerable for patients.

  2. does this protocol decrease the rate of unplanned health care visits and improve patient quality of life.

Patients will undergo the treatment protocol during their routine suprapubic catheter exchanges.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Indwelling suprapubic catheter with insertion date at least 1 year prior to studyenrollment date.

  • History of urinary tract infections, treated for at least 1 positive urine culturein last 6 months

Exclusion

Exclusion Criteria:

  • Current radiographic evidence of urolithiasis

  • History of vesicoureteral reflux

  • History of renal transplantation

  • History of bladder augmentation

  • Inability to stop use of other rUTI prophylaxis treatments for the duration of theirtrial enrollment

  • Life expectancy of less than 12 months prior to consent.

  • Known hypersensitivity or allergy to chlorhexidine.

  • Women who are pregnant or breastfeeding.

Study Design

Total Participants: 70
Treatment Group(s): 1
Primary Treatment: Bladder instillation with Irrisept
Phase:
Study Start date:
April 01, 2024
Estimated Completion Date:
December 31, 2025

Study Description

Bacterial colonization is present in up to 95% of chronically catheterized patients. Although a positive urine culture collected from an indwelling catheter is not in isolation indicative of an acute urinary tract infection (UTI), long term catheter use is associated with increased rates of recurrent urinary tract infections (rUTI), pyelonephritis, and bacteremia. Using antibiotics for prevention of infections in this patient population can be challenging given the side effects, cost, and emergence of resistant bacteria with antibiotic therapy. To limit systemic side effects, intravesical irrigation is a promising route of medication administration. The use of a non-antibiotic anti-microbial at the time of SPC exchange would eliminate the obstacles of non-compliance and antibiotic resistance associated with antibiotic irrigation for preventive therapy. Irrisept, a 0.05% Chlorhexidine Gluconate (CHG) irrigation in sterile water, could be a promising agent to reduce symptomatic UTIs and unplanned tube changes in chronically catheterized patients.

The proposed route of intravesical instillation involves the administration of a therapeutic agent directly into the bladder via a urinary catheter. This route allows for local contact with bladder mucosa and urinary pathogens. It is a currently accepted route of administration used for therapeutics in urologic conditions including, but not limited to UTI prophylaxis, bladder cancer, hemorrhagic cystitis, and interstitial cystitis. Benefits of intravesical instillation include maximizing exposure of the therapeutic within the bladder while limiting systemic absorption and side effects.

A volume 150cc is based on current clinical administration of bladder instillations. Current intravesical drug delivery is most commonly utilized in volumes 50-150cc for in-office instillation. Population studies of normal volunteers demonstrate that 1st bladder sensation occurs between 125-200cc with subsequent desire to void occurring between 170-370cc. Increasing instillation volumes greater than 150cc, especially in the chronically catheterized population, can lead to patient discomfort or dysreflexia and inability to tolerate the therapy without analgesia or anesthetic.

Connect with a study center

  • Yale New Haven Health

    New Haven, Connecticut 06519
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.